Drugs / YH003
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05176509 | Apr 2022 → Aug 2023 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05017623 | Aug 2021 → Mar 2023 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04481009 | Aug 2020 → May 2022 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05420324 | Jun 2022 → Mar 2024 | mucosal melanoma | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05031494 | Dec 2021 → Aug 2023 | melanoma, pancreatic ductal adenocarcinoma | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04481009 ↗ |
| Route | Intravenous | “administered intravenously” NCT04481009 ↗ |